Codexis, Inc.  

(Public, NASDAQ:CDXS)   Watch this stock  
Find more results for CDXS
-0.02 (-0.51%)
After Hours: 3.90 -0.03 (-0.81%)
Feb 10, 4:02PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.88 - 3.99
52 week 3.02 - 5.65
Open 3.95
Vol / Avg. 132,857.00/120,895.00
Mkt cap 157.21M
P/E     -
Div/yield     -
EPS -0.14
Shares 40.31M
Beta 0.21
Inst. own 62%
Mar 1, 2016
Q4 2015 Codexis Inc Earnings Release (Estimated) Add to calendar
Dec 2, 2015
Codexis Inc at LD Micro Main Event Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 31.00% -54.01%
Operating margin 32.70% -54.13%
EBITD margin - -35.19%
Return on average assets 54.34% -35.66%
Return on average equity 107.08% -56.26%
Employees 91 -
CDP Score - -


200 Penobscot Dr
REDWOOD CITY, CA 94063-4718
United States - Map
+1-650-4218100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Codexis, Inc. is a developer of biocatalysts. The Company is engaged in the pharmaceutical and fine chemical industries. The Company's CodeEvolver protein engineering technology platform is used in the evolution and optimization of biocatalysts to perform specific and desired chemical reactions at commercial scale. The pharmaceutical customers use its technology, products and services in their manufacturing process development and production of drugs. The Company's technologies enable scale-up and implementation of biocatalytic solutions for sustainable process development, from research to manufacturing. The Company's products include Codex screening panels and kits that enable customers to establish optimal reactions. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates and Codex Biocatalyst Kits and Panels.

Officers and directors

Thomas R. Baruch J.D. Independent Chairman of the Board
Bio & Compensation  - Reuters
John J. Nicols President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Gordon T. Sangster Chief Financial Officer, Senior Vice President
Age: 61
Bio & Compensation  - Reuters
Douglas T. Sheehy J.D. Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
James Lalonde Senior Vice President, Research & Development
Age: 54
Bio & Compensation  - Reuters
Pam P. Cheng Director
Age: 44
Bio & Compensation  - Reuters
Kathleen Sereda Glaub Director
Bio & Compensation  - Reuters
Patrick Y. Yang Ph.D. Director
Age: 67
Bio & Compensation  - Reuters
Byron L. Dorgan Independent Director
Age: 72
Bio & Compensation  - Reuters
Bernard J. Kelley Independent Director
Age: 73
Bio & Compensation  - Reuters